Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

被引：11

作者：

Gentile, Massimo ^{[1
]}

Shanafelt, Tait D. ^{[2
]}

Mauro, Francesca Romana ^{[3
]}

Reda, Gianluigi ^{[4
]}

Rossi, Davide ^{[5
]}

Laurenti, Luca ^{[6
]}

Del Principe, Maria Ilaria ^{[7
]}

Cutrona, Giovanna ^{[8
]}

Angeletti, Ilaria ^{[9
]}

Coscia, Marta ^{[10
]}

Herishanu, Yair ^{[11
,12
]}

Chiarenza, Annalisa ^{[13
]}

Molica, Stefano ^{[14
]}

Ciolli, Stefania ^{[15
]}

Goldschmidt, Neta ^{[16
]}

Angrilli, Francesco ^{[17
]}

Giordano, Annamaria ^{[18
]}

Rago, Angela ^{[19
]}

Bairey, Osnat ^{[20
,21
]}

Tripepi, Giovanni ^{[22
]}

Chaffee, Kari G. ^{[23
]}

Sameer, Parikh A. ^{[24
]}

Vigna, Ernesto ^{[1
]}

Zirlik, Katja ^{[25
]}

Shvidel, Lev ^{[26
,27
,28
]}

Innocenti, Idanna

Recchia, Anna Grazia ^{[29
]}

Di Raimondo, Francesco ^{[13
]}

Del Poeta, Giovanni ^{[7
]}

Cortelezzi, Agostino ^{[4
]}

Neri, Antonino ^{[4
]}

Ferrarini, Manlio ^{[30
]}

Gaidano, Gianluca ^{[31
]}

Kay, Neil E. ^{[2
]}

Polliack, Aaron ^{[16
]}

Foa, Robin ^{[3
]}

Morabito, Fortunato ^{[29
]}

机构：

[1] Osped Annunziata, UOC Ematol, Cosenza, Italy

[2] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA

[3] Univ Sapienza, Ematol, Rome, Italy

[4] Univ Milan, Osped Maggiore Policlin, Fdn Ca Granda IRCCS, Unita Ematol, Milan, Italy

[5] Oncol Inst Southern Switzerland, Inst Oncol Res, Bellinzona, Switzerland

[6] Univ Cattolica A Gemelli Rome, Dipartimento Ematol, Rome, Italy

[7] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenzione, Ematol, Rome, Italy

[8] IRCCS S Martino IST, UOC Patol Mol, Genoa, Italy

[9] Azienda Osped Santa Maria Tern, Reparto Oncoematol, Terni, Italy

[10] Univ Torino, AO Citta Salute & Sci Torino, Div Ematol, Turin, Italy

[11] Tel Aviv Univ, Tel Aviv Sourasky Med, Dept Hematol, Tel Aviv, Israel

[12] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[13] Univ Catania, Osped Ferrarotto, Div Ematol, Catania, Italy

[14] Azienda Osped Pugliese Ciaccio, Dipartimento Oncoematol, Catanzaro, Italy

[15] Univ Firenze, Ematol, Florence, Italy

[16] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel

[17] Osped Spirito Santo, Dipartmento Ematol, Pescara, Italy

[18] Ematol Azienda Osped Univ, Policlin Consorziale Bari, Bari, Italy

[19] Osped Santa Maria Goretti, UOC Ematol, Latina, Italy

[20] Rabin Med Ctr, Dept Hematol, Petah Tiqwa, Israel

[21] Tel Aviv Univ, Sackler Fac Med, Petah Tiqwa, Israel

[22] CNR, Ist Biomed & Immunol Mol, Reggio Di Calabria, Italy

[23] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA

[24] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA

[25] Univ Med Ctr Freiburg, Dept Haematol & Oncol, Freiburg, Germany

[26] Kaplan Med Ctr, Dept Hematol, Rehovot, Israel

[27] Hadassah Med Ctr, Jerusalem, Israel

[28] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[29] Azienda Sanit Provinciale Cosenza, Unita Ric Biotecnol, Aprigliano, CS, Italy

[30] Direzione Sci IRCCS, San Martino IST, Genoa, Italy

[31] UPO, Dept Translat Med, Div Haematol, Novara, Italy

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2018年 / 101卷 / 05期

关键词：

chemo-immunotherapy; chronic lymphocytic leukemia; CLL-IPI; PFS; prognosis; progression-free survival; CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY UNTREATED PATIENTS; PROGNOSTIC INDEX; RITUXIMAB; CYCLOPHOSPHAMIDE; BENDAMUSTINE; FLUDARABINE; TRIAL; COMBINATION; MULTICENTER;

D O I：

10.1111/ejh.13149

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：703 / 706

页数：4

共 50 条

[41] Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study
Leonetti, A.
Perrone, F.
Puntoni, M.
Bordi, P.
Maglietta, G.
Bria, E.
Gelsomino, F.
Gelibter, A.
Caliman, E.
Genova, C.
Guaitoli, G.
Passiglia, F.
Montrone, M.
Oresti, S.
Pasello, G.
Roca, E.
Pilotto, S.
Cecere, F. L.
Guida, A.
Manzo, A.
Russo, A.
Rastelli, F.
Bulotta, A.
Citarella, F.
Toschi, L.
Zoratto, F.
Cortinovis, D. L.
Paoloni, F.
Follador, A.
Carta, A.
Camerini, A.
Di Maio, M.
Tiseo, M.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S610 - S610
[42] IMP321 and weekly paclitaxel as first-line chemo-immunotherapy for metastatic breast cancer (MBC)
Gutierrez, Maya
Brignone, Chrystelle
Grygar, Caroline
Marcu, Manon
Triebel, Frederic
[J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 873 - 873
[43] EHA 2023: New Results on Ibrutinib in Combination with Venetoclax in the First-line Treatment of CLL
不详
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (10) : 447 - 447
[44] Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)
Cramer, Paula
Langerbeins, Petra
Eichhorst, Barbara
Hallek, Michael
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (01) : 9 - 18
[45] Updated CLL Guideline Broad Recommendation of Ibrutinib for all Patients in First-Line Therapy
不详
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 419 - 419
[46] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
Jain, Nitin
Keating, Michael J.
Thompson, Philip A.
Ferrajoli, Alessandra
Burger, Jan A.
Borthakur, Gautam
Takahashi, Koichi
Estrov, Zeev E.
Sasaki, Koji
Fowler, Nathan H.
Kadia, Tapan M.
Konopleva, Marina
Alvarado, Yesid
Yilmaz, Musa
DiNardo, Courtney D.
Bose, Prithviraj
Ohanian, Maro
Pemmaraju, Naveen
Jabbour, Elias
Kanagal-Shamanna, Rashmi
Patel, Keyur
Wang, Wei
Jorgensen, Jeffrey L.
Wang, Sa A.
Garg, Naveen
Wang, Xuemei
Cruz, Nichole
Ayala, Ana
Plunkett, William
Kantarjian, Hagop M.
Gandhi, Varsha
Wierda, William G.
[J]. BLOOD, 2020, 136
[47] Clinical and demographic characteristics of CLL patients receiving first-line bendamustine plus rituximab using the Flatiron Health database.
Tang, Boxiong
Gabriel, Susan
Pathak, Ashutosh K.
Brander, Danielle M.
Zhou, Jifang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[48] Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting.
Mato, Anthony R.
Tang, Boxiong
Azmi, Soraya
Yang, Keri
Wallis, Nicola
Stern, Jennifer C.
Hedrick, Eric
Huang, Jane
Sharman, Jeff Porter
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer - a meta-analysis
Chen, Ching-Yi
Chen, Wang-Chun
Hung, Chao-Ming
Wei, Yu-Feng
[J]. IMMUNOTHERAPY, 2021, 13 (14) : 1165 - 1178
[50] Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab
Gentile, Massimo
Reda, Gianluigi
Mauro, Francesca Romana
Sportoletti, Paolo
Laurenti, Luca
Coscia, Marta
Recchia, Anna G.
Varettoni, Marzia
Murru, Roberta
Chiarenza, Annalisa
Condoluci, Adalgisa
Moia, Riccardo
Pietrasanta, Daniela
Loseto, Giacomo
Consoli, Ugo
Scortechini, Ilaria
Vigna, Ernesto
Botta, Cirino
Fraticelli, Vincenzo Ludovico
Di Prima, Alessio
Tripepi, Giovanni
Rossi, Davide
Gaidano, Gianluca
Gattei, Valter
Morabito, Fortunato
[J]. BLOOD, 2019, 134

← 1 2 3 4 5 →